Abstract：
Autologous stem cell transplantation is routinely used in the management of several hematological diseases, solid tumors, and immune disorders. Peripheral blood stem cell (PBSC) collection performed by apheresis is the preferred source of stem cells. In this study, the potential impact of mobilization regimens on the performance of the Spectra Optia® continuous mononuclear cell collection system was evaluated. We performed a retrospective data analysis for patients undergoing autologous PBSC collection at the Medical University Vienna, Vienna General Hospital between September 2016 and June 2018. Collections were divided into two main groups according to the mobilization regimen received: without (210 collections) or with (99 collections) plerixafor. Assessed variables included product characteristics and collection efficiency (CE). Overall, product characteristics were similar between the groups. Median CD34+ CE2 was 50.1% versus 53.0%, and CE1 was 66.9% versus 69.9% following mobilization without and with plerixafor, respectively; the difference was not statistically significant. Simple linear regression showed a very weak positive correlation between the mobilization method and CE1 or CE2 (mobilization with plerixafor increased CE2 by 4.106%). In conclusion, the Spectra Optia® apheresis system led to high CE and a good quality of PBSC products when mobilization regimens with or without plerixafor were used.
摘要：
自体干细胞移植通常用于治疗多种血液系统疾病。实体瘤,和免疫性疾病。通过单采术进行的外周血干细胞(PBSC)收集是优选的干细胞来源。在这项研究中,评估了动员方案对SpectraOptia®连续单核细胞收集系统性能的潜在影响.我们在维也纳医科大学对接受自体PBSC采集的患者进行了回顾性数据分析，维也纳总医院，2016年9月至2018年6月。根据收到的动员方案，收藏分为两个主要组：没有（210个收藏）或有（99个收藏）plerixafor。评估的变量包括产品特性和收集效率(CE)。总的来说,两组之间的产品特征相似。CD34+CE2中位数为50.1%和53.0%，CE1为66.9%，而在不使用和使用plerixafor的情况下，CE1为69.9%，分别；差异无统计学意义。简单的线性回归显示，动员方法与CE1或CE2之间的正相关非常弱（用plerixa动员，使CE2增加4.106％）。总之,SpectraOptia®单采术系统在使用或不使用plerixafor的动员方案时，可获得较高的CE和高质量的PBSC产品。
